Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment
The combination of PAM and ANL was more effective than monotherapy for treating ovarian cancer and holds potential to become a new therapeutic approach for ovarian cancer.
Authors
- Hanning Chen (ORCID: https://orcid.org/0000-0003-3568-8039)
- Baiwang Chu
- Xueyu Wang (ORCID: https://orcid.org/0009-0004-6132-7936)
- ZZ Zhao Zhang (ORCID: https://orcid.org/0000-0002-3358-8459)
- Dong Wang (ORCID: https://orcid.org/0000-0001-9921-8058)
- Ying Li (ORCID: https://orcid.org/0000-0003-4012-6954)
- Hua Sun (ORCID: https://orcid.org/0000-0001-9920-6778)
- Tingjie Wen
Institutions
- Tianjin University of Science and Technology (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fphar.2025.1702014
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00